Author:
Gurler Sevim B.,Wagstaff Oliver,Dimitrova Lili,Chen Fuhui,Pedley Robert,Weston William,Donaldson Ian J.,Telfer Brian A.,Novo David,Pavlou Kyriaki,Taylor George,Ou Yaqing,Williams Kaye J.,Gilmore Andrew,Brennan Keith,Ucar Ahmet
Abstract
SUMMARYHER2 is considered as a driver oncogene responsible for the HER2+ subtype of breast cancer. However, it is still unclear how HER2 induces the oncogenic transformation of breast cancer stem cells (BCSCs) and initiates tumorigenesis during premalignant stage breast cancer. Here, we used clinical samples and mouse models of HER2+ breast cancer to demonstrate that neither BCSCs nor their cell-of-origin express HER2/Neu in early-stage breast tumors. Instead, our results demonstrate that Neu overexpression results in the transformation of BCSCs in a non-cell-autonomous manner via triggering DNA damage and somatic mutagenesis in their Neu-negative cell-of-origin. This is caused by the increased oxidative stress in the tissue microenvironment generated by altered energy metabolism and increased reactive oxygen species levels in Neu-overexpressing mammary ducts. Therefore, our findings illustrate a previously unrecognized mechanism of HER2-induced breast tumor initiationin vivowith potential impacts on future preventive treatments for HER2+ premalignant breast cancer.
Publisher
Cold Spring Harbor Laboratory